Process for the production and purification of the collagenase enzyme from vibrio alginolyticus
The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 11038, synonym LMG 3418, hereinafter called Vibrio alginolyticus ), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage. A further subject of the present invention is pharmaceutical compositions containing collagenase obtained according to the production and purification process described, for the purpose of therapeutic treatment of disorders characterised by collagen accumulation or for the treatment of blemishes/imperfections that benefit from reducing local collagen accumulations.
1. A method for the treatment of adhesive capsulitis, Dupuytren's contracture, or Peyronie's disease, which method comprises:
(i) producing and purifying collagenase from Vibrio alginolyticus chemovar. Iophagus by a process comprising the following stages:
Stage A: Inoculation of Vibrio alginolyticus chemovar. Iophagus into an Erlenmeyer flask and fermentation with, culture broth of non-bovine animal origin;
Stage B: Clarification of the fermented broth thus obtained by tangential flow ultrafiltration with 100-500 kD Molecular Weight Cut-Off (MWCO) cassettes;
Stage C: Dialysis and concentration of the clarified medium obtained in stage B, by tangential flow ultrafiltration with 5-30 kD MWCO cassettes;
Stage D: Purification of the solution containing collagenase obtained in Stage C, by anion-exchange resin carrying weak basic groups, at a pH of between 6.9 and 7.4;
Stage E: Dialysis and concentration of the fractions with collagenolytic activity collected in Stage D, by tangential flow ultrafiltration with 10-50 kD MWCO cassettes:
Stage F: Purification of the solution thus obtained, by anion-exchange resin carrying strong basic groups, at a pH of between 6.9 and 7.4;
Stage G: Diafiltration and concentration of the fractions with collagenolytic activity>95% originating from stage F by tangential flow ultrafiltration with 10-50 kD MWCO cassettes;
Stage H: Filtration of the solution containing collagenase thus obtained, through an 0.2 um absolute filter, and storage at a temperature of between −20° and −80° C.: and
(ii) administering to a patient in need thereof an effective amount of an injectable pharmaceutical composition;
wherein the injectable pharmaceutical composition comprises or consists of, per unit dose:
the collagenase, in freeze-dried form, in a quantity equivalent to activity ranging between 120 and 450 nkat;
sterile saline solution; and
wherein the collagenase is characterized by:
molecular weight 82 kDa;
specific activity between 1000 and 1800 nkat/mg;
purity between 98.0 and 100%;
no microbial or protein contaminants;
stability at a pH of between 5.5 and 11;
stability in aqueous solution at a temperature ranging between 4° and 40° C.;
stability in aqueous solution at 4° C. for 30 days;
stability in aqueous solution at a temperature ranging between −20° C. and −80° C. for 24-48 months;
lyophilisability to obtain a stable lyophilic powder;
and caseinase activity is less than 1.0 U/ml.
2. A method for the treatment of adhesive capsulitis, Dupuytren's contracture, or Peyronie's disease, which method comprises:
(i) producing and purifying collagenase from Vibrio alginolyticus chemovar. Iophagus by a process comprising the following stages:
Stage A: Inoculation of Vibrio alginolyticus chemovar. Iophagus into an Erlenmeyer flask and fermentation with, culture broth of non-bovine animal origin;
Stage B: Clarification of the fermented broth thus obtained by tangential flow ultrafiltration with 100-500 kD Molecular Weight Cut-Off (MWCO) cassettes;
Stage C: Dialysis and concentration of the clarified medium obtained in stage B, by tangential flow ultrafiltration with 5-30 kD MWCO cassettes;
Stage D: Purification of the solution containing collagenase obtained in Stage C, by anion-exchange resin carrying weak basic groups, at a pH of between 6.9 and 7.4;
Stage E: Dialysis and concentration of the fractions with collagenolytic activity collected in Stage D, by tangential flow ultrafiltration with 10-50 kD MWCO cassettes:
Stage F: Purification of the solution thus obtained, by anion-exchange resin carrying strong basic groups, at a pH of between 6.9 and 7.4;
Stage G: Diafiltration and concentration of the fractions with collagenolytic activity>95% originating from stage F by tangential flow ultrafiltration with 10-50 kD MWCO cassettes;
Stage H: Filtration of the solution containing collagenase thus obtained, through an 0.2 um absolute filter, and storage at a temperature of between −20° and −80° C.: and
(ii) administering to a patient in need thereof an effective amount of an injectable pharmaceutical composition;
wherein the injectable pharmaceutical composition comprises or consists of, per unit dose:
the collagenase, in freeze-dried form, in a quantity equivalent to activity ranging between 120 and 450 nkat;
hyaluronic acid with a weight average molecular weight ranging between 750 and 1200 kDa, in a concentration ranging between 1 and 30 mg/ml of saline solution; and
wherein the collagenase is characterized by:
molecular weight 82 kDa;
specific activity between 1000 and 1800 nkat/mg;
purity between 98.0 and 100%;
no microbial or protein contaminants;
stability at a pH of between 5.5 and 11;
stability in aqueous solution at a temperature ranging between 4° and 40° C.;
stability in aqueous solution at 4° C. for 30 days;
stability in aqueous solution at a temperature ranging between −20° C. and −80° C. for 24-48 months;
lyophilisability to obtain a stable lyophilic powder;
and caseinase activity is less than 1.0 U/ml.
3. A method for the treatment of adhesive capsulitis, Dupuytren's contracture, or Peyronie's disease, which method comprises administering to a patient in need thereof an effective amount of an injectable pharmaceutical composition consisting of 0.35 ml of a sterile saline solution wherein hyaluronic acid having a weight average molecular weight equal to 750 kDa is dissolved at a concentration of 10 mg/ml, and wherein Collagenase enzyme from Vibrio alginolyticus chemovar. Iophagus , in freeze-dried form, in a quantity equivalent to an activity equal to 196 nkat is reconstituted;
wherein the collagenase is characterized by:
molecular weight 82 kDa;
specific activity between 1000 and 1800 nkat/mg;
purity between 98.0 and 100%;
no microbial or protein contaminants;
stability at a pH of between 5.5 and 11;
stability in aqueous solution at a T ranging between 4° and 40° C.;
stability in aqueous solution at 4° C. for 30 days;
stability in aqueous solution at a T ranging between −20° C. and −80° C. for 24-48 months;
lyophilisability to obtain a stable lyophilic powder;
and caseinase activity is less than 1.0 U/ml.
4. A method for the treatment of adhesive capsulitis, Dupuytren's contracture, or Peyronie's disease, which method comprises administering to a patient in need thereof an effective amount of an injectable pharmaceutical composition consisting of 0.7 ml of a sterile saline solution wherein hyaluronic acid having a weight average molecular weight equal to 1200 kDa is dissolved at a concentration of 15 mg/ml, and wherein Collagenase enzyme from Vibrio alginolyticus chemovar. Iophagus , in freeze-dried form, in a quantity equivalent to an activity equal to 392 nkat is reconstituted;
wherein the collagenase is characterized by;
molecular weight 82 kDa;
specific activity between 1000 and 1800 nkat/mg;
purity between 98.0 and 100%;
no microbial or protein contaminants;
stability at a pH of between 5.5 and 11;
stability in aqueous solution at a T ranging between 4° and 40° C.;
stability in aqueous solution at 4° C. for 30 days;
stability in aqueous solution at a T ranging between −20° C. and 80° C. for 24-48 months;
lyophilisability to obtain a stable lyophilic powder;
and caseinase activity is less than 1.0 U/mL.